64 stories
Retatrutide is Eli Lilly's GLP-1/GIP/glucagon triple agonist, now the most efficacious obesity peptide ever read out in Phase 3. Phase 2 work showed mean weight loss above 24% at 48 weeks plus an 86% reduction in liver fat at 48 weeks, ahead of every approved drug.
TRIUMPH-1 topline released May 21, 2026 is the registrational readout that anchors the planned BLA. In 2,339 adults with obesity or overweight and at least one weight-related comorbidity without diabetes, retatrutide produced 28.3% mean weight loss at 12 mg, 25.9% at 9 mg, and 19.0% at 4 mg over 80 weeks versus 2.2% on placebo. 45.3% of participants on 12 mg reached ≥30% weight loss — bariatric-surgery territory. A 104-week extension in the BMI ≥35 subgroup pushed mean weight loss to 30.3% (85.0 lbs). Transient ALT elevations that surfaced in TRIUMPH-4 reappeared and normalized by week 24, consistent with hepatic triglyceride mobilization. Discontinuation rates ran 4.1%, 6.9%, and 11.3% across 4, 9, and 12 mg arms versus 4.9% placebo. TRIUMPH-4 in obesity with knee osteoarthritis posted 28.7% mean weight loss at 68 weeks plus 75.8% reduction in WOMAC pain. TRANSCEND T2D1 in type-2 diabetes reported A1c down 1.7 to 2.0 percentage points and 25 to 37 lb mean weight loss versus placebo. On July 23, 2026, Lilly reported TRIUMPH-2 and TRIUMPH-3 topline results using the efficacy estimand. In TRIUMPH-2 (1,152 adults with type 2 diabetes and obesity or overweight), the 12 mg dose produced 20.8% weight loss and an A1C reduction of up to 1.6 percentage points at 80 weeks, versus 4.0% and 0.2 points on placebo. In TRIUMPH-3 (1,949 adults with severe obesity and established cardiovascular disease), 12 mg produced 22.6% weight loss versus 3.2% on placebo at 80 weeks. Lilly plans to submit a Biologics License Application to the FDA in the first quarter of 2027 for obesity, knee osteoarthritis pain, and obstructive sleep apnea. The 10,000-patient TRIUMPH-OUTCOMES cardiovascular trial reads out 2027. Full TRIUMPH-1 data landed at ADA 2026 (June 5-8, New Orleans). Full TRIUMPH-2 results were published in The Lancet and presented at EASD on September 30, 2026, reporting dysesthesia in 4.5% to 7.3% of retatrutide patients versus 0.7% on placebo.
Retatrutide has also leaked into the unregulated research-peptide channel; the April 2026 Utah federal indictment of an osteopathic physician for selling 200+ patients misbranded Chinese peptides named retatrutide alongside semaglutide, tirzepatide, and BPC-157. The access fight took a sharper political turn on June 23, 2026 when STAT News disclosed that the FDA and Lilly granted a mystery 79-year-old patient compassionate-use access to retatrutide on the application of NIH senior clinician Dr. Ranganath Muniyappa, citing refractory obesity plus OSA plus pulmonary hypertension; outside experts told STAT the diagnoses don't clearly meet the compassionate-use threshold and the White House had to publicly deny that President Trump (who turned 80 on June 14) applied. The political escalation continued through June 24-25: White House senior deputy press secretary Kush Desai attacked STAT reporter Lizzy Lawrence as 'an unserious gossip columnist' (June 23-24), Rep. Ted Lieu (D-CA) suggested Trump canceled the 21st Century ROAD to Housing bill signing because he is receiving an experimental drug for terminal illness (June 24, prompting White House Communications Director Steven Cheung to call Lieu a 'dumba--'), and Senator Maggie Hassan (D-NH) sent a formal letter to HHS Secretary RFK Jr. on June 25 demanding answers and characterizing the use as 'a highly anticipated medication for obesity to a single VIP individual for free.' Lilly issued its first public statement on June 25: 'We make these decisions following all applicable regulations.' Stories here cover the trial readouts, mechanism work, the access-equity debate, the political fallout, and the gray-market enforcement track.
TikTok users on retatrutide report emotional blunting. Neuroscientist Paul Kenny of Mount Sinai says researchers are investigating whether GLP-1 drugs act as general reward dampeners affecting the brain's mesolimbic system.
Deep dive into the retatrutide hype cycle triggered by Andrew Huberman's endorsement and looksmaxxing influencers. Frames the triple-agonist as potentially more consequential than Ozempic.
Psychiatric Times provides educational review of the incretin system covering the shift toward oral nonpeptide small-molecule GLP-1 RAs and triple agonists expected within 1-2 years.
Eli Lilly's triple agonist (GIP/GLP-1/glucagon) retatrutide met its primary A1C reduction endpoint and all key secondary endpoints at 40 weeks in the TRANSCEND-T2D-1 trial.
Eli Lilly's triple GLP-1/GIP/glucagon receptor agonist retatrutide demonstrated up to 28.7% weight loss along with significant knee pain reductions in obesity patients with osteoarthritis. Seven additional Phase 3 trials expected to report throughout 2026.
Analyst deep-dive into Lilly's position as healthcare's most valuable company, with ~60% U.S. incretin market share driven by tirzepatide and a retatrutide pipeline showing ~30% weight loss potential.
Findings presented at The Liver Meeting show retatrutide cleared fatty liver disease in more than 85% of patients with obesity, dramatically expanding its therapeutic profile beyond weight loss.
Detailed Phase 3 results for Eli Lilly's triple-agonist (GLP-1/GIP/glucagon) showed significant weight loss alongside improved pain and physical function in obesity-related knee osteoarthritis. Seven additional Phase 3 trials underway.
Eli Lilly's triple-agonist achieved record weight loss at the highest dose with substantial reductions in knee osteoarthritis pain. Seven more Phase 3 trials expected in 2026.
Analysis of the TRIUMPH program (TRIUMPH-1 through TRIUMPH-4) published in Diabetes, Obesity, and Metabolism shows unprecedented average weight reduction of up to 24% across 5,800+ adults.